Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128734) titled 'Combined Strategies of ADCs and Immunotherapy for Advanced ESCC Based on Molecular Subtyping' on July 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences
Condition:
HER2-Positive Advanced Esophageal Squamous Cell Carcinoma
Intervention:
Group A:Trasturzrmab
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-08-07
Target Sample Size: Group A:20;Group B:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=329659
Disclaimer: Curated by HT Syndication....